DRAK2 Antibody - BSA Free

Western Blot: DRAK2 Antibody [NBP1-76885] - Analysis in Raji cell lysate with antibody at (A) 1 and B (2) ug/mL.

Immunocytochemistry/ Immunofluorescence: DRAK2 Antibody - BSA Free [NBP1-76885] - Immunocytochemistry of DRAK2 in Jurkat cells with DRAK2 antibody at 10 ug/mL.

• Reactivity: Hu, Mu, Rt
• Applications: WB, ELISA, ICC/IF
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 1 mg/ml

DRAK2 Antibody - BSA Free Summary

• Description: Novus Biologicals Rabbit DRAK2 Antibody - BSA Free (NBP1-76885) is a polyclonal antibody validated for use in WB, ELISA and ICC/IF. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Immunogen: Antibody was raised against a 15 amino acid peptide near the carboxy terminus of human DRAK2. The immunogen is located within the last 50 amino acids of DRAK2. Amino Acid Squence: SKRFRFDDSLPNPHE
• Specificity: It has no cross responses to DAP or ZIP kinases. The approximately 70 kDa band is probably non-related to DRAK2 although it is peptide blockable.
• Predicted Species: Mouse (93%), Rat (93%). Backed by our 100% Guarantee.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: STK17B
• Purity: Ion exchange chromatography

Applications/Dilutions

• Dilutions:
  • ELISA 1:100-1:2000
  • Immunocytochemistry/ Immunofluorescence 10 ug/mL
  • Western Blot 0.5 ug/ml
• Application Notes: An approximately 45 kDa band can be detected in Western Blot.
• Theoretical MW: 45 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• Control Peptide:

  DRAK2 Peptide (NBP1-76885PEP)

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: 0.02% Sodium Azide
• Concentration: 1 mg/ml
• Purity: Ion exchange chromatography

Alternate Names for DRAK2 Antibody - BSA Free

• DAP kinase-related apoptosis-inducing protein kinase 2
• DRAK2
• DRAK2death-associated protein kinase-related 2
• EC 2.7.11
• EC 2.7.11.1
• serine/threonine kinase 17b (apoptosis-inducing)
• serine/threonine kinase 17b
• serine/threonine-protein kinase 17B
• STK17B

Background

Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase-related apoptosis-inducing protein kinases). DRAKs contain an N-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: STK17B
• Uniprot:
  • AB011421(Human)